Human VEGFR3 / FLT4 Protein (His Tag)

FLT-4,FLT-41,FLT41,LMPH1A,PCL,VEGFR-3,VEGFR3

100ug (NPP1617) Please inquiry

Catalog Number	P10806-H08H
Organism Species	Human
Host	Human Cells
Synonyms	FLT-4,FLT-41,FLT41,LMPH1A,PCL,VEGFR-3,VEGFR3
Molecular Weight	The recombinant human VEGF R3 consists of 763 amino acids and predicts a molecular mass of 86 kDa. As a result of glycosylation, rhVEGFR3 migrates as an approximately 130 kDa in non-reduced SDS-PAGE.
predicted N	Tyr 25 & Ser 473
SDS-PAGE
Purity	> 97 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the extracellular domain (Met 1-Ile 776) of human VEGFR3 (NP_002011.2) was expressed with a C-terminal polyhistidine tag.
Bio-activity	1. Measured by its binding ability in a functional ELISA. 2. Immobilized human VEGF-C (P 10542-H08H) at 10 μg/mL (100 μl/well) can bind human VEGFR3-his. The EC₅₀ of human VEGFR3-his is 0.011 μg/mL. 3. Measured by its ability to bind human VEGF-D (P 10557-H08H) in a functional ELISA.
Research Area	Cancer \|Signal transduction \|Protein Kinase \|Receptor Tyrosine Kinase (RTK)
Formulation	Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.
Reference	Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52. Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36. Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5. Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.